Patients with stage 2 CKD ( estimated glomerular filtration rate [ eGFR ] 60 to < 90 mL/min per 173 m ( 2 ) ; n = 290 ) were randomly assigned ( 1:1:1 ) to receive empagliflozin 10 mg or 25 mg or placebo once daily for 52 weeks .